The phylogenetic map from the human kinome demonstrating development and US FDA acceptance of modest molecule kinase inhibitors to tyrosine kinases and serine/threonine kinases for many different reliable and hematologic malignancies. Tyrosine kinase inhibitors address a wide array of cancers and